IART241220C30000
- 0.41
- 0.000.00%
Integra Lifesciences Newsroom
Morgan Stanley Initiates Integra Lifesciences(IART.US) With Sell Rating, Announces Target Price $20
J.P. Morgan Maintains Integra Lifesciences(IART.US) With Sell Rating, Cuts Target Price to $24
Truist Financial Maintains Integra Lifesciences(IART.US) With Hold Rating, Maintains Target Price $26
Truist Financial Maintains Integra Lifesciences(IART.US) With Hold Rating, Raises Target Price to $26
Integra LifeSciences Is Maintained at Sell by Citigroup
Integra Lifesciences Analyst Ratings
Morgan Stanley Remains a Sell on Integra Lifesciences (IART)
JMP Securities Maintains Integra Lifesciences(IART.US) With Buy Rating, Maintains Target Price $35
Analysts Offer Insights on Healthcare Companies: Sana Biotechnology (SANA) and Integra Lifesciences (IART)
Truist Financial Maintains Integra Lifesciences(IART.US) With Hold Rating, Cuts Target Price to $21
Integra Lifesciences Analyst Ratings
Truist Raises Price Target on Integra LifeSciences Holdings to $26 From $21, Keeps Hold Rating
B of A Securities Maintains Underperform on Integra Lifesciences, Lowers Price Target to $18
BTIG Upgrades Integra Lifesciences(IART.US) to Hold Rating, Maintains Target Price $20
Integra Lifesciences Sell Rating: Overly Ambitious Targets Amid Persistent Operational Challenges
Integra LifeSciences Is Maintained at Sell by Citigroup
Integra Lifesciences Analyst Ratings
Citi Maintains Integra Lifesciences(IART.US) With Sell Rating, Cuts Target Price to $16
Wells Fargo Downgrades Integra Lifesciences(IART.US) to Hold Rating, Cuts Target Price to $25
Integra Lifesciences: Hold Rating Amidst Compliance Challenges and Revenue Impact With a Long-Term Recovery Outlook